Study | N included | N completed treatment | Population and primary diagnosis | Treatment types | Duration (weeks) | Primary and secondary outcome measure | Time between pre- and post-treatment |
---|---|---|---|---|---|---|---|
Blom et al. (2007) | 193 | 132 | Adults with MDD | IPT vs.Nefazodone vs.IPT+nefazodone vs.IPT+placebo | 16 | HAMD | 12 weeks |
MADRS | |||||||
Elkin et al. (1989) | 250 | 155 | Adults with MDD | IPT vs. CBT vs. IMI-CM vs. PLA-CM | 16 | HRSD | 16 weeks |
BDI | |||||||
Luty et al. (2009) | 177 | 159 | Adults with MDD | IPT vs.CBT | 16 | MADRS | 16 weeks |
HRSD | Â | ||||||
BDI | Â | ||||||
Marshall et al. (2008) | 159 | 102 | Adults with MDD | IPT vs.CBT vs.PHT-CM | 16 | HRSD | 16 weeks |
Martin et al. (2001) | 28 | 28 | Adults with MDD | IPT vs.Venlafaxine | 16 | HAMD | 6 weeks |
BDI | |||||||
O’Hara et al. (2000) | 120 | 99 | Women with PPD | IPT vs. WLC | 12 | HRSD | 12 weeks |
BDI | |||||||
Schramm et al. (2011) | 30 | 29 | Adults with early onset chronic MDD | IPT vs.CBASP | 16 with 12 months follow-up | HRSD | 16 weeks |
BDI | Â | ||||||
Schulberg et al. (1996) | 276 | 150 | Adults with MDD | IPT vs.Nortriptyline vs.Usual care | 16 with 8 months follow-up | HRSD | 8 months |